Description
THIS MODIFICATION IS ISSUED TO INCORPORATE SPECGX LLC 2026 SUBCONTRACTING PLAN EFFECTIVE FOR THE PERIOD OF JANUARY 1, 2026 -- DECEMBER 31, 2026.
Base award description: NEW AWARD FOR BUPRENORPHINE HCL/NALOXONE HCL SUBLINGUAL TABLETS WITH SPECGX LLC. PERIOD OF PERFORMANCE IS JUNE 7, 2021 TO JUNE 6, 2022 WITH FOUR ONE-YEAR OPTIONS.
Modification chain · 13 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2020-12-22+$0= $0
- Mod P000012021-04-15+$0= $0
- Mod P000022022-01-12+$0= $0
- Mod P000032022-05-02+$0= $0
- Mod P000042022-12-14+$0= $0
- Mod P000052023-04-06+$0= $0
- Mod P000062023-04-17+$0= $0
- Mod P000072024-02-13+$0= $0
- Mod P000082024-02-20+$0= $0
- Mod P000092024-04-22+$0= $0
- Mod P000102025-01-14+$0= $0
- Mod P000112025-04-29+$0= $0
- Mod P000122026-01-06+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2020-12-22 | +$0 | $0 | NEW AWARD FOR BUPRENORPHINE HCL/NALOXONE HCL SUBLINGUAL TABLETS WITH SPECGX LLC. PERIOD OF PERFORMANCE IS JUN… |
| Mod P00001· ADD SUBCONTRACTING PLAN | 2021-04-15 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE SPECGX LLC 2021 SUBCONTRACTING PLAN EFFECTIVE FOR THE PERIOD OF JAN… |
| Mod P00002· ADD SUBCONTRACTING PLAN | 2022-01-12 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE SPECGX LLC 2022 SUBCONTRACTING PLAN EFFECTIVE FOR THE PERIOD OF JAN… |
| Mod P00003· EXERCISE AN OPTION | 2022-05-02 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO EXERCISE OPTION YEAR 1 FOR BUPRENORPHINE/NALOXONE TABLETS UNDER 36E79721D0013 W… |
| Mod P00004· ADD SUBCONTRACTING PLAN | 2022-12-14 | +$0 | $0 | INCORPORATE SPECGX'S 2023 SMALL BUSINESS SUBCONTRACTING PLAN INTO CONTRACT. PLAN IS EFFECTIVE 1/1/2023 - 12/31… |
| Mod P00005· EXERCISE AN OPTION | 2023-04-06 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO EXERCISE THE 2ND OPTION YEAR FOR BUPRENORPHINE/NALOXONE TABLETS UNDER CONTRACT… |
| Mod P00006· OTHER ADMINISTRATIVE ACTION | 2023-04-17 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE THE DRUG SUPPLY CHAIN SECURITY ACT (DSCSA) LANGUAGE INTO THE CONTRA… |
| Mod P00007· ADD SUBCONTRACTING PLAN | 2024-02-13 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE SPECGX LLC 2024 SUBCONTRACTING PLAN EFFECTIVE FOR THE PERIOD OF JAN… |
| Mod P00008· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2024-02-20 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO UPDATE THE TERMS OF THE CRF PAYMENT REMITTAL AND SUBMISSION OF QUARTERLY SALES… |
| Mod P00009· EXERCISE AN OPTION | 2024-04-22 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO EXERCISE THE 3RD OPTION YEAR FOR BUPRENORPHINE /NALOXONE TABLETS UNDER CONTRACT… |
| Mod P00010· ADD SUBCONTRACTING PLAN | 2025-01-14 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE SPECGX LLC 2025 SUBCONTRACTING PLAN EFFECTIVE FOR THE PERIOD OF JAN… |
| Mod P00011· EXERCISE AN OPTION | 2025-04-29 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO EXERCISE THE 4TH AND FINAL OPTION YEAR FOR BUPRENORPHINE/NALOXONE TABLETS FOR T… |
| Mod P00012· ADD SUBCONTRACTING PLAN | 2026-01-06 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE SPECGX LLC 2026 SUBCONTRACTING PLAN EFFECTIVE FOR THE PERIOD OF JAN… |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI SJ9MSB1UXGL8)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24526N0786 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $4,435 | FY2026 |
| 36C24526N0382 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $5,213 | FY2026 |
| 36C24525N0842 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $5,572 | FY2025 |
| 36C24525N0365 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $5,328 | FY2025 |
| 36C24524N0852 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $4,639 | FY2024 |
| 36C24524N0407 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $4,884 | FY2024 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79721D0013_3600 · retrieved 2026-09-26.